Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Licenses Nucleic Acid Patents to NimbleGen

This article has been updated from a previous version, which incorrectly reported that NimbleGen had licensed and planned to sell Affymetrix's microarrays.
 
NEW YORK (GenomeWeb News) – Affymetrix has granted NimbleGen a license to patents covering the manufacture, use, and sale of nucleic acid microarrays, the companies said today.
 
"This license is a major milestone in NimbleGen's evolution as a company, and part of a fundamental expansion of our commercial strategy," said Stan Rose, president and CEO of NimbleGen, in statement. "Our intent is to expand dramatically the ability of scientists to access NimbleGen products and services."
 
Financial details were not disclosed.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.